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Abstract
Rationale Selective serotonin reuptake inhibitor (SSRI) antidepressants are increasingly prescribed during pregnancy. Changes
in serotonergic signaling during human fetal development have been associated with changes in brain development and with
changes in affective behavior in adulthood. The suprachiasmatic nucleus (SCN) is known to be modulated by serotonin and it is
therefore assumed that SSRIs may affect circadian rhythms. However, effects of perinatal SSRI treatment on circadian system
functioning in the offspring are largely unknown.
Objective Our aimwas to investigate the effects of perinatal exposure to the SSRI fluoxetine (FLX) on circadian behavior, affective
behavior, and 5-HT1A receptor sensitivity in female rats. In addition, we studied the expression of clock genes and the 5-HT1A
receptor in the SCN, as they are potentially involved in underlying mechanisms contributing to changes in circadian rhythms.
Results Perinatal FLX exposure shortened the free-running tau in response to the 5-HT1A/7 agonist 8-OH-DPAT. However, FLX
exposure did not alter anxiety, stress coping, and 5-HT1A receptor sensitivity. No differences were found in 5-HT1A receptor and
clock genes Per1, Per2, Cry1, and Cry2 SCN gene expression.
Conclusions Perinatal FLX exposure altered the response to a phase-shifting challenge in female rats, whether this may pose
health risks remains to be investigated.
Keywords Fluoxetine . Pregnancy . Perinatal . Circadian behavior . Anxiety . Coping style . Clock genes . 5-HT1A receptor .
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Introduction
Depressive symptoms occur frequently during pregnancy,
resulting in a major depressive disorder (MDD) in about 5%
of pregnant women (Gaynes et al. 2005; Melville et al. 2010).
Sometimes antidepressant treatment is unavoidable, especial-
ly when a mother is suicidal. In Europe, about 3% of pregnant
women are prescribed antidepressants, while in the USA,
numbers rise up to 13% (Cooper et al. 2007; El Marroun
et al. 2012; Hayes et al. 2012). Selective serotonin reuptake
inhibitors (SSRIs) are the first-line treatment for MDD during
pregnancy and lactation, as they have not been associated with
increased risks for structural teratogenic effects in the off-
spring (Gentile 2005). However, SSRIs do reach the develop-
ing child through the placenta and are evident in breast milk
(Heikkinen et al. 2003; Noorlander et al. 2008). SSRIs operate
by blocking the serotonin (5-HT) transporter and inhibiting 5-
HT reuptake back into the presynaptic cell. At first, the in-
creased 5-HT levels act on the more distal 5-HT1A
autoreceptors inhibiting further neuronal firing, but chronic
use of SSRIs results in downregulation of these 5-HT1A re-
ceptors. The removal of this 5-HT1A receptor-mediated nega-
tive feedback loop ultimately results in sustained higher extra-
cellular 5-HT levels and increased serotonergic neurotrans-
mission (Pierz and Thase 2014). During development, seroto-
nin acts as a neurotrophic factor regulating various cell pro-
cesses such as cell division, cell differentiation, synaptogene-
sis, neurite sprouting, and dendritic pruning (Gaspar et al.
2003). Altering serotonin levels through SSRI exposure
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during development can therefore lead to changes in brain
development and adult behavior (reviewed in (Olivier et al.
2013)). For example, internalizing and externalizing behav-
iors, as well as anxiety and depression, are more often ob-
served in children of women who used SSRIs during the peri-
natal period (Hanley et al. 2013, 2015; Brandlistuen et al.
2015; Malm et al. 2016), while other studies show that not
the SSRIs but the maternal mood during the postpartum peri-
od is responsible for these outcomes (Oberlander et al. 2007;
Oberlander, T. F., Papsdorf, M., Brain, U.M., Misri, S., Ross,
C. and Grunau 2010). Similarly, effects of perinatal SSRI
treatment on neurodevelopment, serotonergic functioning,
and adult behavior are found in rodent studies. For example,
perinatal exposure to the SSRI fluoxetine (FLX) has been
associated with increased 5-HT1A receptor sensitivity
(Olivier et al. 2011; Altieri et al. 2015) and higher levels of
anxiety in rodent offspring (Olivier et al. 2011; Ko et al. 2014;
Boulle et al. 2016a). Furthermore, SSRIs are known to influ-
ence the sensitivity to the circadian system (McGlashan et al.
2018). However, effects of maternal SSRI treatment during
the perinatal period on circadian system functioning in the
offspring are largely unknown. The suprachiasmatic nucleus
(SCN) of the hypothalamus is also known as the master pace-
maker of circadian rhythms, which drives daily essential func-
tions of the body such as feeding, sleeping, body temperature,
and the secretion of hormones by synchronizing the internal
environment with the external environment (Gillette and
Tischkau 1999). These functions repeat themselves over a
period of near 24 h and are termed circadian rhythms. The
period of the circadian rhythm in constant conditions (such
as constant darkness) is called the free-running period, or
tau. Furthermore, even though circadian rhythms are self-sus-
taining, they rely upon circadian time cues (zeitgebers), which
can be either photic (light) or nonphotic (e.g., activity, tem-
perature), to adjust to the local environment. Furthermore,
circadian rhythms are generated and regulated by highly con-
served “clock” genes that are expressed in the SCN, with
oscillating mRNA and protein levels of near 24 h, with
Period 1 (Per1), Period 2 (Per2), Cryptochrome 1 (Cry1) and
Cryptochrome 2 (Cry2) being among some of the first identi-
fied clock genes. Interestingly, SSRI exposure in adulthood
has been found to shorten expression of Per1 in rat-1 fibro-
blasts and in the mouse SCN (Nomura et al. 2008), thus af-
fecting circadian rhythmicity. The SCN mainly receives sero-
tonergic input from the median raphe nuclei and in turn indi-
rectly projects to midbrain raphe nuclei (Morin 2013). In the
SCN, serotonergic signaling can modulate phase-shifting ef-
fects of photic and nonphotic cues both in vitro (Medanic and
Gillette 1992; Prosser 2003; Prosser et al. 2006) and in vivo
(Ehlen et al. 2001; Smith et al. 2008). In addition, 8-OH-
DPAT, a 5-HT1A/7 receptor agonist, is well known as a
nonphotic stimulus to induce phase advances in circadian
rhythm (partly) via the 5-HT1A receptor (Smith et al. 2008).
Interestingly, SSRIs alter the sensitivity of 5-HT receptors,
mostly reducing the sensitivity of the 5-HT1A receptor
(Olivier et al. 2011). It is therefore assumed that SSRI expo-
sure, e.g., during development, also affects circadian rhythms.
Indeed, when male mice are exposed to FLX during the peri-
natal period, they show a shorter free-running period in total
darkness, an increased phase shift to photic cues, and a de-
creased phase shift to nonphotic cues, suggesting persistent
changes in the circadian system (Kiryanova et al. 2013,
2017). Despite behavioral alterations being observed, the
mechanisms involved were not explored in these studies.
One of the possible mechanisms through which the alterations
in circadian rhythm caused by SSRIs take place might be the 5-
HT1A receptor. Both presynaptic and postsynaptic 5-HT1A re-
ceptors exist. Presynaptic 5-HT1A autoreceptors are present on
soma and dendrites of the raphé serotonergic neurons
projecting to many forebrain areas (Fernández-Guasti et al.
1992; Le Poul et al. 1995; Marek 2010; Altieri et al. 2013).
Postsynaptic 5-HT1A heteroreceptors are present in various
brain areas, mainly in the forebrain (Frink et al. 1996;
Garcia-Garcia et al. 2017). Postsynaptic 5-HT1A receptors are
implicated in mood disorders and have been used as target for
various neuropsychiatric disorders (Newman-Tancredi 2011).
Genetic studies in both 5-HT1A receptor knockout mice and
humans indicate that the 5-HT1A receptor may be an underly-
ing mechanism in major depressive disorders (Savitz et al.
2009) and anxiety disorders (Lesch et al. 1992; Olivier et al.
2001; Nash et al. 2008). In humans, changes in circadian be-
havior can result in altered physiological responses and chang-
es in sleep-wake behavior which can contribute to disease
pathology (Smolensky et al. 2016). In this study, our aim
was to investigate the effects of perinatal FLX treatment on
(1) circadian rhythms for both body temperature and activity,
including phase shifts in response to photic (light) and
nonphotic cues such as the 5-HT1A/7 agonist 8-OH-DPAT,
(2) the sensitivity to 5-HT1A receptor agonist induced hypo-
thermia, (3) anxiety and stress coping behavior, and (4) gene
expression levels of the 5-HT1A receptor and clock genes in the
SCN. Because circadian parameters may be linked to depres-
sion in different ways in males and females (Swanson et al.
2017), and a higher prevalence of affective disorders is found
in women compared to men, our aim was to understand the
effects of perinatal FLX exposure in female rats.
Materials and methods
Animals and housing
Animals were housed in Makrolon type 3 cages (38.2 ×
22.0 × 15.0 cm) during individual housing or Makrolon type
4 cages (55.6 × 33.4 × 19.5 cm) during social housing.
Animals had ad libitum access to food (RMH-B, AB Diets;
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Woerden, the Netherlands) and tap water and were maintained
on a reversed 12 h light/dark cycle (lights off at 11:00 A.M.)
unless stated otherwise. A wooden gnawing stick (10 × 2 ×
2 cm) and nesting material (Enviro-dri®) was provided for
environmental enrichment. All breeding took place in our
own facility and experimental procedures were approved by
the Groningen University Committee of Animal experiments.
Breeding
Animals were surplus animals from a previous experiment
(Houwing et al. 2019b) where female heterozygous serotonin
transporter (SERT) knockout rats (Slc6a41Hubr; SERT+/-)
were bred with SERT+/− male rats. Wildtype (SERT+/+),
SERT+/-, and homozygous SERT knockout (SERT−/−) pups
were exposed to early life stress (ELS) by being maternally
separated for 6 h a day, while control (CTR) pups were sepa-
rated and handled for 15 min, daily from postnatal day (PND)
2–15. Pups were weaned at PND21 and socially housed with
same-treated, same-sex pups from different litters. When
adult, ELS SERT+/- female pups showed depressive-like be-
havior and were used as an animal model for maternal depres-
sion (Houwing et al. 2019a). However, in the present study,
we used only wildtype (SERT+/+) female offspring from the
nondepressive CTR SERT+/- dams (with and without FLX
treatment), as the offspring from these dams were surplus.
Perinatal FLX treatment
Wistar CTR SERT+/- females were bred with SERT+/+ males
when in estrus, which was determined by measuring vaginal
wall impedance (model MK-11, Muromachi, Tokyo, Japan).
Females were housed with males for 24 h, and this day was set
as gestational day 0 (G0). Dams were randomly assigned to
the vehicle (VEH) or FLX-treated group. FLX (2 mg/mL;
Pharmachemie BV, the Netherlands) or VEH (methylcellu-
lose 1%, Sigma Aldrich Chemie BV, Zwijndrecht, the
Netherlands) was dissolved in sterile water and administered
at a volume of 0.5 mL/100 g using oral gavage (PVC flexible
feeding tubes, Vygon, Valkenswaard, the Netherlands). Dams
were treated daily with 10 mg/kg FLX or VEH from G0 until
weaning of the pups at PND21. During oral gavage, animals
were held but not restrained, minimizing stress. To determine
the exact injection volume, dams were weighed daily. Dams
were checked twice a day for pup delivery. On PND21, pups
were weaned and housed with 3–5 same-treated, same-sex
animals, from different litters. Ears were punched for individ-
ual recognition and genotyping (for genotyping protocol, see
(El Aidy et al. 2017)). Only SERT+/+ females were used for
the current study.
Behavioral testing
Adult female wildtype (SERT+/+) offspring (12 VEH, 11
FLX) were tested for anxiety and stress coping using various
behavioral tests. Naïve animals were first tested in the elevated
plus maze (EPM) and the forced swim test (FST). At the end
of all other experiments, animals were tested in the home cage
emergence test (HCE) and again in the EPM. Testing occurred
between 12:00 and 17:00 during the dark phase of the animals,
under dim light conditions. Before testing, the estrous stage of
each animal was measured using a vaginal wall impedance
checker (model MK-11, Muromachi, Tokyo, Japan).
Animals were only tested when not in estrous. Animals were
socially housed (3–4 per cage) during the first EPM and the
FST, and individually housed when the HCE and the second
EPM were performed.
Elevated plus maze
At 16 weeks of age, animals were tested for anxiety-like be-
havior in the elevated plus maze (EPM). In short, the EPM
consisted of two open (45.0 × 10.0 × 1.0 cm) and two closed
(45.0 × 10.0 × 50.0 cm) arms located opposite of each other.
The EPM was elevated at a height of 50 cm. Rats were placed
in the center of the plus maze facing an open arm and were
allowed to freely explore for 5 min. Frequency and time spent
on the open arms and distance moved on the open arms were
automatically scored using EthoVision XT 12.0 (Noldus
Informat ion Technology B.V. , Wageningen, the
Netherlands). Animals were tested under dim light conditions
(open arm 2.5 lx; closed arm 0.25 lx) and the EPM was
cleaned with 70% ethanol between trials. Animals were tested
in the EPM again at 41 weeks of age, after ending of all
pharmacological challenges.
Forced swim test
At 17 weeks of age, animals were tested for their stress coping
style in the forced swim test (FST). Animals were placed in
cylindrical Plexiglas tanks (50.0 × 18.0 cm diameter), which
were filled with 30 cm of water (22 ± 1 °C). On the first day, 3
or 4 animals were placed in the separate tanks for 15 min.
Animals were dried with a towel and placed in a cage on a
heating mat to recover while the next trial commenced. On
day 2, exactly 24 h later, animals were re-tested for 5 min.
Animals could not see each other as tanks were separated with
dividers. Animals were not tested if they were in estrus on the
first day, but we did not take the estrus cycle into account on
day 2. The FST was recorded on video camera and the dura-
tion of mobility and immobility on day 2 was scored by an
observer blind for treatment using The Observer XT 11.0
(Noldus Information Technology B.V., Wageningen, the
Netherlands). Active climbing, swimming, and diving were
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scored as mobility, while immobility was defined as making
no movements for at least 2 s or making only those move-
ments that were necessary to keep the nose above the water.
Slightly moving paws or support by pressing paws against the
wall of the tank was still considered immobility. Tanks were
cleaned and refilled between trials.
Home cage emergence
At 41 weeks of age, after all other challenges were completed,
animals underwent the home cage emergence test, which is
another test for anxiety-like behavior. The animal, which was
individually housed in its home cage, was moved to an adja-
cent test room and placed in an open field (100 × 100 cm). The
lid of the cage was removed and a wired metal grid was placed
over the edge of the cage for easier escape. Using a stopwatch,
the latency to escape the home cage was measured. An animal
was considered as escaped when all four paws of the animal
were over the edge of the cage, either by climbing onto the
grid or by jumping on top of one of the cage walls. The cutoff
to escape the home cagewas set at 10min and rats who did not
escape were given that score for the latency.
Corticosterone levels
Animals were socially housed at the time of blood sampling.
Blood sampling was performed before the start of the FST and
directly after the FST on day 1 (between 12:00 and 17:00) to
measure the response to a stressor. Blood was sampled from
the experimental animal within 20 min after arriving in the
experiment room. To make sure no smell of blood lingered
after sampling and testing, spilled blood was cleaned before
starting the next trial. For blood collecting, a small tail incision
was made with a razor blade and ± 150 μL blood was collect-
ed in EDTA coated capillary tubes. Blood samples were cen-
trifuged (3000 rpm) for 10min at 4 °C. The plasma was stored
at − 80 °C. CORT levels were determined by radioimmuno-
assay (MP Biomedicals, Orangeburg, NY). Samples were an-
alyzed in duplo and measures were averaged afterwards.
Surgery and telemetry
At 18 weeks, animals were anesthetized with a mixture of
N2O/O2 (1:2) and isoflurane (2.5%, Rhodia Organique Fine
Limited, Bristol, UK). A temperature-sensitive transmitter
(Type TA10-TA-F40, Data Sciences Inc., St. Paul,
Minnesota, USA) was implanted in the peritoneal cavity.
Immediately after surgery and again after 24 h, animals re-
ceived 0.2 mL finadyne (MSD, the Netherlands), an anti-
inflammatory and pain relieving drug. Animals were individ-
ually housed and placed with their home cage on a receiver
(model RPC-1 and RLA1020, Data Sciences Inc.). Output
signals from the transmitters were transferred via the receivers
to a PC-based data acquisition and analysis system (Dataquest
ART version 3.11, Data Sciences Inc.). Activity counts and
CBT were sampled every 5 min for 10 s on a 24-h basis.
Animals were allowed to recover for 14 days before starting
behavioral testing.
Assessment of circadian behavior
Patterns of activity and body temperature were assessed in
three lighting conditions: normal light/dark 12/12 h cycle
(LD), reversed light/dark cycle (RLD), and constant darkness
(DD) (Fig. 1). From birth until surgery, animals were housed
under a 12/12 h LD cycle (lights on at 22:00, off at 10:00,
Zeitgeber time (ZT) 0–12). Zeitgeber time (ZT0) was defined
as light onset and ZT12 as light offset. At 22 weeks, the LD
cycle was reversed by advancing the LD cycle by 12 h (lights
on at 10:00, of at 22:00, ZT 12–24). Animals were maintained
on this RLD cycle for 3 weeks before changing the cycle to
DD for 9 weeks during which the animals received a phase-
shifting 8-OH-DPAT injection. Only the last week of RLD
data is used for the analysis due to 1 day where the lights were
left on accidentally, so a sufficient washout period was left
before analyzing the data. After the DD period, animals were
put on a normal LD cycle again during which they were ex-
posed to pharmacological challenges of the serotonergic sys-
tem. Finally, animals were tested for HCE and again in the
EPM in this LD cycle, followed by 2 weeks of rest before
sacrificing for brain collection.
Entrained circadian rhythmicity
Entrainment of activity and core body temperature (CBT) cir-
cadian rhythm to a normal 12:12 h LD cycle and RLD cycle
was measured during the last 7 days of each period for an
average 24 h profile (LD: week 20, RLD: week 24). Activity
counts were first z-transformed (and made a positive integer
by adding the most negative number in the dataset to all values
for that individual) to avoid bias of telemetry sender differs.
Subsequently, activity data were averaged over 7 days and
grouped into 4 h blocks to determine the average profile over
24 h. Furthermore, the period of the rhythm (tau) of the
entrained LD and RLD rhythm was calculated.
Circadian response to 8-OH-DPAT
At 32 weeks, all animals received a subcutaneous injection of
5-HT1A/7 receptor agonist 8-OH-DPAT (5 mg/kg, Sigma
Aldrich Chemie BV, Zwijndrecht, the Netherlands) at a time
point where low activity was measured in the DD (ZT 15) to
trigger a phase-shifting response. Using the 6 days of the DD
period prior to and the day including the 8-OH-DPAT injec-
tion, the free-running tau for activity and CBT before 8-OH-
DPAT injection (pre-injection) was determined as has been
2558 Psychopharmacology (2020) 237:2555–2568
done in a previous study (Kiryanova et al. 2017). In addition,
free-running tau for activity and CBT were calculated after 8-
OH-DPAT injection (post-injection) using a period of 7 days
excluding three transient—that is unstable—cycles after injec-
tion (Kiryanova et al. 2017). Subsequently, pre- and post-
injection free-running tau were compared and the phase shift
was calculated. A periodogram was created for additional vi-
sualization of the results.
Data analysis
Entrained and free-running tau were calculated by fitting CBT
data using locally weighted scatterplot smoothing (R function
loess, R Core Team, 2015; version 3.2.3, Rstudio version
0.99.491) to find the timepoint of CBTmin for each of the
7 days of data. The time between these CBTminima was then
calculated and averaged across the 7-day period. These
entrained and free-running tau values were then compared
between treatment groups. Entrained and free-running tau
for the activity data were calculated using a Lomb-Scargle
periodogram analysis (Ruf 1999) performed in Chronoshop
(version 1.05, courtesy of Kamiel Spoelstra). The
periodogram analysis consisted of a quantitative analysis, with
a range of 18 h to 28 h, a resolution set at 2 bins, and an alpha
of 0.01. To plot the data, animals were split by treatment
group and the normalized power (PN) was plotted for both
pre- and post-8-OH-DPAT injection against the tau range in-
cluded in the analysis. The phase shift was calculated as the
time between the two best fitted periods of activity. This anal-
ysis was performed in Chronoshop, with a runningmean of 10
bins based on center of gravity of the data. One rat (VEH) was
excluded from all tau analyses due to a lack of data (battery
died in the transponder). Two rats (1 VEH and 1 FLX) had
only 5 days instead of 7 days of pre-injection tau data and two
other rats had 3 days (FLX) and 5 days (VEH) for the post-
injection tau data. An average of the available data was uti-
lized in these cases.
5-HT1A receptor sensitivity
Thermal response to 5-HT1A receptor agonist F13714
After 8-OH-DPAT analysis, animals were put on a normal
12:12 h LD cycle again (lights off at 07:00) at week 34.
After 2 weeks of acclimatization, animals were injected sub-
cutaneously with 0.0625, 0.125, or 0.25 mg/kg of selective 5-
HT1A receptor agonist F13714 (Neurocrine biosciences, San
Diego, California, USA) or saline (0.9% NaCl) to induce hy-
pothermia (week 36). Recovery was assessed afterwards.
Animals received all different concentrations in randomized
order with a washout period of 3 days in between injections
(within animal design). Injections were given at a time point
where low activity was measured (ZT 15).
Thermal response to 5-HT1A receptor antagonist WAY100635
After the washout period of F13714, we continued by giving a
subcutaneous injection of 5-HT1A receptor antagonist
WAY100635 (Wyeth Ayerst Pharmaceuticals, Princeton,
New Jersey, USA) in week 38. Animals were injected with
0.001, 0.1, and 1 mg/kgWAY100635 or saline in randomized
order and again with a washout period of 3 days in between
injections. Injections were given at a time point were low
activity was measured (ZT 15).
Thermal response to a combination of F13714
and WAY100635
At 40weeks, a combination of F13714 (0.125mg/kg, s.c.) and
WAY100635 (0.1 mg/kg, s.c.) was given during the low ac-
tivity period (ZT15), to investigate whether WAY100635
could antagonize the F13714-induced hypothermic response,
to confirm the involvement of the 5-HT1A receptor. First an-
imals were injected inside the flank with WAY100635 which
Fig. 1 Overview of performed behavioral tests and pharmacological challenges. Lighting conditions: Light-dark (LD), reversed light-dark (RLD), and
constant darkness (DD). Numbers represent the age of the animal in weeks
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was immediately followed by an injection with F13714 in the
other flank.
Data analysis
For all injections, the area under the curve (AUC) for body
temperature was calculated from 1 h before the injection to 4 h
after the injection (Olivier et al. 2011).
Gene expression analysis
Sacrificing and brain dissection
After finishing the HCE and EPM in week 41, the beginning
of the 12/12 h LD cycle was set at 23:00 lights on for logistic
reasons. After 2 weeks of acclimatization to the new cycle,
half of the animals (6 VEH, 5 FLX) were sacrificed at the end
of the light phase between 8:30 and 9:30 (ZT9.5-CT10.5),
while the other half (6 VEH, 6 FLX) was sacrificed at the
end of the dark phase between 20:30 and 21:30 (21.5 – CT
22.5). At these time points, the rhythmically expressed clock
genes in the SCN that we chose were not at their minimum or
maximum expression (Shigeyoshi et al. 1997; Kume et al.
1999) to avoid a floor or ceiling effect that could conceal
differences between groups. Animals were anesthetized with
CO2 by placement on a grid in a small box directly above dry
ice for approximately 60 s, prior to decapitation. Brains were
rapidly dissected and frozen in isopentane on dry ice and
stored at − 80 °C. Brains were cut into coronal slices
(200 μM, − 12 °C) and punches from the SCN (3 slices) were
obtained according to the atlas of Paxinos and Watson. Brain
punches were obtained bilaterally using a single 1.2 mm
punch per slice (Harris Uni-CoreTM) and collected in RNA/
DNA-free tubes on dry ice and stored at − 80 °C until further
use.
RNA isolation, cDNA synthesis, quantitative real-time
polymerase chain reaction
Total RNAwas isolated from SCN tissue using Trizol reagent
(Invitrogen Life Technologies) and stored at − 80 °C until
further use. A NanoDrop 2000c spectrophotometer was used
to assess RNA concentrations and purity. Complementary
DNA (cDNA) was synthesized from RNA using
oligo(dT)18 primers through RevertAid Reverse
Transcriptase (Thermo Scientific). After cDNA synthesis,
samples were diluted to 10 ng/uL cDNA and further processed
for qPCR analysis. Using 20 ng of cDNA,mRNA levels of the
following genes were assessed: Period 1 (Per1), Period 2
(Per2), Cryptochrome 1 (Cry1), Cryptochrome 2 (Cry2), and
the 5-HT1A receptor (5-HT1AR). Gapdh and β-actin were
used as reference genes for normalization of gene expression.
Custom-designed TaqMan® gene expression assays (Thermo
Scientific) were used for all genes Per1 (Rn01325256_m1),
Per2 (Rn01427704_m1), Cry1 (Rn01503063_m1), Cry2
(Rn01485701_m1), 5-HT1AR (Rn00561409_s1), and house-
keeping genes Gapdh (RN01775763_g1) and β-actin
(RB0667869_m1). qPCR for Gapdh with Per2 and β-actin
with Cry2 were performed in multiplex. qPCR for Per1 and
Cry1 were performed in singleplex. Quantitative real-time
PCR (qRT–PCR) was performed using the CFX96 Real-
Time PCR Detection System (Bio-Rad, Hercules, CA,
USA). Thermal cycling conditions were as follows: 2 min at
50 °C, 2 min at 90 °C, followed by 50 cycles of 15 s at 95 °C,
and 1 min at 60 °C.
Data analysis
All samples were run in triplicates, except for 5-HT1AR,
which was run in duplo due to insufficient amount of
Taqman assay. Mean plate efficiencies and Cq values were
calculated with the qRT-PCR analys is sof tware
LinRegPCR. When the standard deviation between a trip-
licate was > 0.3, the most outlying sample was removed.
For the duplo samples, when the standard deviation was >
0.5, both samples from the animal were removed. Mean
normalized expression (MNE), based on the ratio between
Cq values of the target and reference genes and the effi-
ciency of the PCR reactions, was calculated as a measure
of target gene transcription. Data were presented as
logMNE and the fold change was calculated.
Statistical analysis
First, all data were checked for parametric distribution. Forced
swim test immobility and entrained tau in LD and RLD were
analyzed using unpaired t tests, with treatment as the indepen-
dent factor. A 2-WAY repeated measures ANOVA was per-
formed for the EPM, with age (16 vs. 41 weeks) as within
subjects factor and treatment (VEH vs. FLX) as between sub-
jects factor. CORT levels before and after FST exposure were
also analyzed using a 2-WAY repeated measures ANOVA
with stress exposure (basal vs. after FST) as within subjects
factor, and treatment (VEH vs. FLX) as between subjects
factor. For activity and CBT free-running tau pre- and post-
injection data, a mixed ANOVA was performed with time as
within subjects factor and treatment as between subjects fac-
tor. Furthermore, for the 5-HT1A receptor sensitivity data, a
mixed ANOVA was performed for the AUC, with dose as
within subjects factor and treatment as between subjects fac-
tor. Gene expression was analyzed using unpaired t test per
gene. Data are presented as mean ± SEM and significance was
set at p < 0.05. When 0.1 < p > 0.05, this was considered a
tendency.




FLX exposure significantly lowered the entries onto the open
arm of the EPM, regardless of testing age (F(1,18) = 6.291,
p = 0.022). Post hoc testing showed that at 16 weeks of age,
before the start of all other experimental procedures, FLX-
exposed animals showed fewer entries into the open arm of
the EPM than VEH-exposed animals (t(19) = 2.103, p =
0.049, VEH n = 10, FLX n = 11, Table 1). An age of 41 weeks
at EPM testing resulted in a lower total distance moved when
compared to testing at 16 weeks, regardless of treatment
(F(1,18) = 11.104, p = 0.004). Post hoc testing showed that
FLX-exposed animals had a lower total distance moved in
the EPM at 41 weeks of age than at 16 weeks of age (t(9) =
3.215, p = 0.011). No other differences between groups were
found for the behavioral parameters measured (Table 1).
Forced swim test
During the 5 min test phase of the FST, FLX-exposed animals
tended to spend less time being immobile than VEH-exposed
animals (t(22) = 1.866, p = 0.075, VEH N = 12, FLX N = 12,
Table 1).
Home cage emergence
No differences were found between groups in the latency to
escape the home cage (VEH n = 12, FLX n = 11, Table 1).
CORT levels
CORT levels significantly increased after FST stress expo-
sure, independent of treatment (F(1,22) = 343,686, p < 0.001).
Post hoc testing indicated increased CORT levels after FST
exposure in both VEH (t = − 11.393, df = 11, p < 0.001) and
FLX (t = − 15,458, df = 11, p < 0.001) exposed animals. No
differences were found in CORT levels between VEH- and
FLX-exposed animals at the basal level (VEH 746.2 ng/mL ±
123.8 ng/mL, FLX 748.1 ng/mL ± 109.6 ng/mL), nor after
FST stress exposure (VEH 2838.1 ng/mL ± 183.0 ng/mL,
FLX 3005.4 ng/mL ± 143.4 ng/mL).
Circadian behavior
Entrained circadian rhythmicity
The 24 h activity profile indicates similarities between treat-
ment groups in terms of activity level during both the normal
light/dark 12/12 h cycle (LD) and reversed light/dark cycle
(RLD) cycle. Particularly, when activity was grouped into
4 h periods, no difference in activity was found between
VEH- and FLX-exposed animals (Fig. 2a). This lack of dif-
ference remained on reversal of the LD cycle (Fig. 2b).
Furthermore, the 24 h core body temperature (CBT) profile
also did not differ between the two treatment groups during
both LD and RLD cycle (Fig. 2c, d). For both CBT and ac-
tivity, entrained tau was not significantly different between
groups (Table 2).
Circadian response to 8-OH-DPAT
FLX treatment and injection time (pre- or post-injection)
significantly interacted to affect the free-running tau for
Table 1 Behavioral outcomes in offspring exposed to perinatal FLX or VEH treatment
Behavioral parameter VEH FLX Statistics (unpaired t test)
EPM (16 weeks)
Total distance moved (m) 16.42 ± 0.72 16.39 ± 0.62 n.s.
Time in open arm (sec) 109.51 ± 9.76 115.60 ± 11.11 n.s.
Open arm entries (freq) 12.80 ± 0.93 10.27 ± 0.78 t(19) = 2.103, p = 0.049
EPM (41 weeks)
Total distance moved (m) 15.38 ± 0.57 13.63 ± 0.58 n.s.
Time in open arm (sec) 109.24 ± 9.18 97.30 ± 9.27 n.s.
Open arm entries (freq) 10.67 ± 0.92 8.91 ± 0.64 n.s.
FST
Immobility time (sec) 99.85 ± 16.55 64.90 ± 8.79 t(22) = 1.866, p = 0.075
HCE
Latency to exit cage (sec) 541.58 ± 39.59 534.91 ± 36.93 n.s.
Data are presented as mean ± SEM
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activity (F(1,15) = 5.477, p = 0.034, Fig. 3a). FLX exposure
significantly shortened the free-running tau after the 8-
OH-DPAT injection, when compared to before the injec-
tion (t(8) = 2.866, p = 0.021), while free-running tau of
VEH exposed animals was unaffected (Table 2). For
additional visualization of these results, a periodogram
was made (Fig. 4). No differences between treatments
were found in CBT either pre- or post-injection
(Table 2) and no main or interaction effects were found
for CBT free-running tau (Fig. 3b).
Fig. 2 Twenty-four-hour profiles of activity (a, b) and CBT rhythmicity (c, d) during the LD (a, c) and RLD (b, d) period
Table 2 Entrained and free-running circadian rhythmicity under different light regimes
Light regime VEH FLX Statistics
Activity
Entrained tau LD 23.86 ± 0.06 23.97 ± 0.07 n.s.
RLD 24.00 ± 0.09 23.89 ± 0.10 n.s.
Free-running tau DD (pre-8-OH-DPAT injection) 24.00 ± 0.07 24.18 ± 0.08 n.s.
DD (post-8-OH-DPAT injection) 24.08 ± 0.07 23.91 ± 0.061 t(8) = 2.866, p < 0.021
Core body temperature
Entrained tau LD 23.87 ± 0.07 23.92 ± 0.05 n.s.
RLD 24.27 ± 0.04 24.27 ± 0.07 n.s.
Free-running tau DD (pre-injection) 24.02 ± 0.06 23.85 ± 0.05 n.s.
DD (post-injection) 24.01 ± 0.07 24.03 ± 0.08 n.s.
1, vs FLX pre-injection; LD, normal light/dark cycle; RLD, reversed light/dark cycle; DD, constant darkness. Data are presented as mean ± SEM
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5-HT1A receptor sensitivity
Thermal response to 5-HT1A receptor agonist F13714
We investigated 5-HT1A receptor sensitivity by applying a
specific and highly efficacious 5-HT1A receptor agonist
(F13714) in a dose-response manner and consequently
by measuring the hypothermic effect. A significant effect
of F12714 dose was found on the area under the curve
(AUC) (F(3, 51) = 311.593, p < 0.001), and a trend towards
a dose x treatment interaction was found (F(3, 51) = 2.205,
p = 0.099) (Fig. 5). All doses significantly decreased the
body temperature in both VEH (0.0626 mg/kg, p = 0.001;
0.125 mg/kg, p < 0.001; 0.25 mg/kg, p < 0.001) and FLX
(0.0626, p = 0.044 mg/kg; 0.125 mg/kg, p < 0.001;
0.25 mg/kg, p < 0.001) offspring compared to a saline
injection, as indicated by a negative AUC (Fig. 5). In
addition, FLX offspring had a significant smaller thermal
response to F13714 than VEH offspring after a saline
injection (p = 0.023).
Thermal response to 5-HT1A receptor antagonist WAY100635
When injected with 5-HT1A receptor antagonis t
WAY100635, an effect of dose on the AUC was found
(F(3,54) = 3.171, p = 0.031). Post hoc testing revealed that
VEH offspring injected with a dose of 0.1 mg/kg
WAY100635 had a lower CBT than VEH offspring injected
with 0.01 mg/kg (p = 0.048, Table 3).
Thermal response to a combination of F13714
and WAY100635
Next, a combination of 0.1 mg/kg WAY100635 and
0.125 mg/kg F13714 was administered to the animals. No
differences were found in the AUC between VEH- and
FLX-exposed animals (Table 3). However, the drop in CBT
(negative AUC) was smaller than when F13714 was given
alone, suggesting that WAY100635 partially blocks the
hypothermia-induced response to F13714.
Gene expression analysis
SCN gene expression was analyzed for 5-HT1AR and four
clock genes: Per1, Per2, Cry1, and Cry2. SCN gene
Fig. 3 Free-running tau of activity (a) and CBT (b) pre- and post-8-OH-DPAT injection. *p < .0.05
Fig. 4 Periodogram visualizing changes in activity free-running tau of
VEH and FLX exposed animals pre- and post-8-OH-DPAT injection
Fig. 5 Thermal response to 5-HT1A receptor agonist F13714. *p < 0.05
compared to same-treated (VEH or FLX) saline injected animal.
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expression did not differ between VEH- and FLX-exposed
animals for any of the genes analyzed (Table 4).
Discussion
Our findings provide evidence that perinatal FLX treatment
disrupts the circadian response to a phase-shifting challenge in
female rats. The 5-HT1A/7 receptor agonist 8-OH-DPAT
shortened the free-running tau for activity in rats that were
perinatally exposed to FLX, while this effect was absent in
the VEH exposed animals. No differences were found be-
tween FLX- and VEH-exposed rats in free-running tau on
the CBT before and after injection of 8-OH-DPAT, indicating
that only after a challenge the disruption in the circadian re-
sponse becomes apparent in the activity and not in CBT. In
mice, perinatal FLX exposure has also been shown to reduce
the free-running period compared to control mice. This effect
was already present without an 8-OH-DPAT challenge, al-
though the advanced phase shift caused by the 8-OH-DPAT
challenge was smaller in mice that were perinatally exposed to
FLX (Kiryanova et al. 2013) which is in line with our find-
ings. As for involved mechanisms, SSRIs have been found to
shorten the period of clock gene Per1 in both rat-1 fibroblasts
and in the mouse SCN (Nomura et al. 2008). We investigated
whether the key clock genes Per1, Per2 and Cry1 and Cry2
were altered due to perinatal FLX exposure but did not find
any differences in the expression of these genes in the SCN
when compared to VEH exposed animals. There might be
several reasons for this finding. First, the expression of period
and cryptochrome genes in the adult brain might not be affect-
ed by perinatal FLX exposure. Second, only differences in
free-running tau for activity were found after the 8-OH-
DPAT challenge, and we did not use this challenge before
sacrificing the rats. In hamsters, 8-OH-DPAT caused an in-
hibitory effect on SCN Per1 and Per2 expression (Horikawa
et al. 2000). For future studies, it would be worthwhile to
investigate whether similar effects would occur in our rats
after an 8-OH-DPAT challenge, and whether perinatal FLX
exposure alters those inhibitory responses. Third, it has been
shown that there is a circadian time-dependent effect caused
by 8-OH-DPAT (Horikawa et al. 2000), and even though we
sacrificed the animals at two time points (end of light and end
of dark phase), we might have missed the time point where
differences arise in gene expression. In the study of Horiwaka
and colleagues, differences in Per1 and Per 2 expression after
an 8-OH-DPAT challenge were only found at the mid-
subjective day, and not during the early subjective day or
subjective night, indicating that the effect might only be found
in a small timeframe (Horikawa et al. 2000). Fourth, we mea-
sured mRNA levels which do not necessarily reflect protein
levels of the genes. Further research is necessary to see wheth-
er protein levels confirm mRNA levels. Altogether, perinatal
Table 3 Thermal response to 5-HT1A receptor agonist F1371, 5-HT1A receptor antagonist WAY100635 and their combination
Area under curve (AUC)
VEH FLX Statistics
F13714
Saline 208.63 ± 57.14 41.37 ± 63.51* *p = 0.023 vs. Saline VEH
0.0625 mg/kg − 70.66 ± 34.23 − 123.15 ± 80.07 n.s.
0.125 mg/kg − 1002.43 ± 76.08 − 1012.21 ± 99.23 n.s.
0.250 mg/kg − 1864.82 ± 141.46 − 1679.31 ± 71.85 n.s.
WAY100635
Saline 72.32 ± 33.75 81.85 ± 55.73 n.s.
0.01 mg/kg 234.67 ± 68.15 128.38 ± 38.45 n.s.
0.1 mg/kg 68.63 ± 27.46* 16.44 ± 59.81 *p = 0.048 vs. 0.01 mg/kg VEH
1 mg/kg 111.19 ± 62.92 108.71 ± 38.35 n.s.
WAY100635 (0.1 mg/kg) + F13714 (0.125 mg/kg) − 366.16 ± 75.32 − 354.37 ± 100.12 n.s.
Data are presented as mean ± SEM. AUCwas calculated from 1 h before the injection to 4 h after the injection. A positive AUC indicates a hyperthermic
response, while a negative AUC indicates a hypothermic response
Table 4 SCN gene expression of the 5HT1A receptor and four clock
genes
Genes VEH LogMNE FLX LogMNE Fold change
Per1 − 12.18 ± 0.37 − 12.02 ± 0.43 − 0.01
Per2 − 7.15 ± 0.61 − 7.61 ± 0.89 0.07
Cry1 − 10.04 ± 0.51 − 9.67 ± 0.49 − 0.04
Cry2 − 11.59 ± 0.39 − 10.90 ± 0.40 − 0.06
5-HT1AR − 8.79 ± 1.00 − 10.23 ± 0.63 0.06
Data, except for the fold change, are presented as mean logMNE ± SEM
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FLX exposure disrupts the circadian response to a phase-
shifting challenge, but underlying mechanisms causing this
effect still remain to be investigated.
Because 8-OH-DPAT exerts its phase-shifting effect
(partly) via the 5-HT1A receptor (Smith et al. 2008), and be-
cause SSRIs are known to change the sensitivity of 5-HT
receptors (Olivier et al. 2011), we investigated whether 5-
HT1AR expression in the SCN and whether the sensitivity to
a 5-HT1A receptor agonists on hypothermia was changed due
to perinatal FLX exposure. No differences were found in the
5-HT1AR expression in the SCN. SSRIs are known to influ-
ence the sensitivity of 5-HT receptors including the 5-HT1A
receptor. Here, we showed that 5-HT1AR expression in the
SCN is not altered due to perinatal FLX exposure, although
we did not test the final 5-HT1A receptor protein levels. On a
functional level, we tested the responsivity to the 5-HT1A re-
ceptor agonist F13714 on hypothermia. A clear dose-response
effect was found in both VEH and FLX exposed rats; howev-
er, no differences in the hypothermic response were found.
These findings indicate that the functionality of the 5-HT1A
receptor is not altered in female rats after perinatal FLX expo-
sure, at least not those 5-HT1A receptor populations involved
in the hypothermic response. In previous experiments, we
showed that perinatal FLX exposure slightly increased the
sensitivity of the 5-HT1A receptor to flesinoxan-induced hy-
pothermia, albeit in male rats (Olivier et al. 2011). Therefore,
the discrepancy between the current and previous study might
be explained by sex differences. Interestingly, we found that
stress-induced hyperthermia (SIH) is reduced in female rats
that were perinatally exposed to FLX. A similar effect was
found in SERT−/− rats. After a saline injection, SERT−/− rats
showed a reduced SIH, indicating that high extracellular
levels of 5-HT during development cause a shift in the sensi-
tivity to this stressor (Olivier et al. 2008). A relative hyper-
stimulation of 5-HT1A receptors, due to FLX exposure, might
underlie the decrease in stress-induced hyperthermia, as this
paradigm is mediated by the 5-HT1A receptor (Olivier et al.
1998). However, further research is necessary to investigate
whether the sensitivity of 5-HT1A receptors implicated in SIH
is reduced after perinatal FLX exposure.
Finally, we investigated the behavioral outcome in female
rats that were perinatally exposed to FLX. Our data show that
perinatal FLX exposure does not induce anxiety-like behavior
in female rats. Animals were tested twice in the elevated plus
maze (EPM), once before all other experiments, and once at
the end after all experiments. This was done because we pre-
viously showed higher anxiety levels in the EPM after a stress-
ful experiment (conditioned place aversion with shock) com-
pared to before this experiment (Olivier et al. 2011). In the
current study, no robust increase in anxiety levels in the EPM
was found, If any, a decreased number of entries on the open
arm in the first EPM experiment, indicating a slight increase in
anxiety levels. Reasons for the discrepancy with the previous
study might be that we used females in the current study as
opposed to males. In addition, different stressors were used in
both studies, making the comparison more challenging.
Nevertheless, our study suggests that perinatal FLX exposure
in female rats does not profoundly increase anxiety levels
since the open arm time is similar to the VEH exposed ani-
mals, which is in line with other studies in both male and
female rodents (Ansorge et al. 2004, 2008; Lisboa et al.
2007; Olivier et al. 2011; Ko et al. 2014; Altieri et al. 2015;
Silva et al. 2018). The fact that perinatal FLX exposure does
not increase anxiety levels in female rats was also confirmed
in our home cage emergence test, where no difference in la-
tency to escape was found between FLX and VEH exposed
animals. To assess the effects of perinatal FLX exposure on
stress coping, immobility time was assessed in the forced
swim test. No effects of perinatal FLX exposure on immobil-
ity in the FST were found, which agrees with another study in
females (Altieri et al. 2015). However, increased immobility
time (Lisboa et al. 2007; Ko et al. 2014; Rebello et al. 2014;
Boulle et al. 2016b), but also decreased immobility time
(Karpova et al. 2009) has been found in the forced swim test
after developmental FLX exposure. It is hard to compare all
these results as experimental design, sex of animals, and ex-
posure timing all vary in these studies. Finally, basal CORT
levels were measured before and after the swim test, to inves-
tigate whether the stress response was altered due to perinatal
FLX exposure. CORT levels did increase after the forced
swim test in both VEH- and FLX-exposed animals; however,
no differences were found between groups. A previous study
in rats showed that FLX exposure during the early postnatal
period results in lower basal serum CORT levels in male, but
not female, adolescents (Pawluski et al. 2012). In female mice,
prenatal FLX exposure results in a greater CORT response to
acute restraint stress (Avitsur 2017). The fact that we did not
find any differences in basal and stress response CORT levels
between our VEH and FLX exposed animals might be ex-
plained by the stressor we used. The forced swim test ap-
peared to be highly stressful as CORT levels after the test were
extremely high, which may have caused a ceiling effect.
Therefore, using a more commonly used (milder) stressor,
e.g., restraint stress, to measure CORT levels would be more
appropriate in future studies.
In conclusion, perinatal FLX treatment in female rats did
not have a major effect on anxiety-like behavior, stress cop-
ing, and 5-HT1A receptor sensitivity. In addition, circadian
rhythmicity seems largely intact. The only significant obser-
vation found in the present study was the shortened free-
running tau followed by a nonphotic challenge in perinatal
FLX-treated rats compared to VEH- treated rats. Whether this
altered response contributes to vulnerability of health risks
remains to be investigated. Overall, results indicate that fe-
male rats may be resilient to the effects of FLX exposure
during pregnancy and the postnatal period. Testing females
2565Psychopharmacology (2020) 237:2555–2568
is therefore highly important as findings might deviate from
findings found in males.
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